ArticleProceedings. Biological sciences2014
A theoretical examination of the relative importance of evolution management and drug development for managing resistance.
Article in Proceedings. Biological sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Temporal Patterns of Haplotypic and Allelic Diversity Reflect the Changing Selection Landscape of the Malaria Parasite Plasmodium falciparum.Molecular biology and evolution · 2025Article
- An agent-based model on antimicrobial de-escalation in intensive care units: Implications on clinical trial design.PloS one · 2024Article
- Recent Advancement in Novel Wound Healing Therapies by Using Antimicrobial Peptides Derived from Humans and Amphibians.Current protein & peptide science · 2024Review
- Inhibition of malaria and babesiosis parasites by putative red blood cell targeting small molecules.Frontiers in cellular and infection microbiology · 2024Article
- Alternate Antimicrobial Therapies and Their Companion Tests.Diagnostics (Basel, Switzerland) · 2023Review
- The Effect of Three Complexes of Iodine with Amino Acids on Gene Expression of Model Antibiotic Resistant MicroorganismsMicroorganisms · 2023Article
- Antimicrobial Peptides: Challenging Journey to the Pharmaceutical, Biomedical, and Cosmeceutical Use.International journal of molecular sciences · 2023Review
- The future of evolutionary medicine: sparking innovation in biomedicine and public health.Frontiers in science · 2023Article
- Prevalence and characteristics of the mcr-1 gene in retail meat samples in Zhejiang Province, China.Journal of microbiology (Seoul, Korea) · 2022Article
- Antibiotic Discovery and Resistance: The Chase and the Race.Antibiotics (Basel, Switzerland) · 2022Review
- Colistin ResistantVeterinary sciences · 2021Review
- The economics of managing evolution.PLoS biology · 2021Article
- Article
- Re-Envisioning Anti-Apicomplexan Parasite Drug Discovery Approaches.Frontiers in cellular and infection microbiology · 2021Review
- Bacterial Protein Homeostasis Disruption as a Therapeutic Intervention.Frontiers in molecular biosciences · 2021Review
- Is antimicrobial resistance evolution accelerating?PLoS pathogens · 2020Review
- Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials.ACS infectious diseases · 2020Article
- Mini review: Genome mining approaches for the identification of secondary metabolite biosynthetic gene clusters inComputational and structural biotechnology journal · 2020Review
- In vitro and in vivo characterization of anti-malarial acylphenoxazine derivatives prepared from basic blue 3.Malaria journal · 2019Article
- On the molecular and cellular effects of omeprazole to further support its effectiveness as an antigiardial drug.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance is a serious public health problem that threatens to thwart our ability to treat many infectious diseases. Repeatedly, the introduction of new drugs has been followed by the evolution of resistance. In principle, there are two complementary ways to address this problem: (i) enhancing drug development and (ii) slowing the evolution of drug resistance through evolutionary management. Although these two strategies are not mutually exclusive, it is nevertheless worthwhile considering whether one might be inherently more effective than the other. We present a simple mathematical model that explores how interventions aimed at these two approaches affect the availability of effective drugs. Our results identify an interesting feature of evolution management that, all else equal, tends to make it more effective than enhancing drug development. Thus, although enhancing drug development will necessarily be a central part of addressing the problem of resistance, our results lend support to the idea that evolution management is probably a very significant component of the solution as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.